4-Methylmorpholine → 4-(4-{5-[2-Chloro-5-(3-Trifluoromethyl-Benzoylamino)-Benzoylamino]-Pyrimidin-2-ylamino}-Benzenesulfonyl)-Piperidine-1-Carboxylic Acid tert-Butyl Ester
Reaction equation
[F:1][C:2]([F:23])([F:22])[C:3]1[CH:4]=[C:5]([CH:19]=[CH:20][CH:21]=1)[C:6]([NH:8][C:9]1[CH:10]=[CH:11][C:12]([Cl:18])=[C:13]([CH:17]=1)[C:14]([OH:16])=O)=[O:7].ClC1N=C(OC)N=C(OC)N=1.CN1CCOCC1.[C:42]([O:46][C:47]([N:49]1[CH2:54][CH2:53][CH:52]([S:55]([C:58]2[CH:63]=[CH:62][C:61]([NH:64][C:65]3[N:70]=[CH:69][C:68]([NH2:71])=[CH:67][N:66]=3)=[CH:60][CH:59]=2)(=[O:57])=[O:56])[CH2:51][CH2:50]1)=[O:48])([CH3:45])([CH3:44])[CH3:43]>C(Cl)Cl>[C:42]([O:46][C:47]([N:49]1[CH2:50][CH2:51][CH:52]([S:55]([C:58]2[CH:59]=[CH:60][C:61]([NH:64][C:65]3[N:70]=[CH:69][C:68]([NH:71][C:14](=[O:16])[C:13]4[CH:17]=[C:9]([NH:8][C:6](=[O:7])[C:5]5[CH:19]=[CH:20][CH:21]=[C:3]([C:2]([F:23])([F:22])[F:1])[CH:4]=5)[CH:10]=[CH:11][C:12]=4[Cl:18])=[CH:67][N:66]=3)=[CH:62][CH:63]=2)(=[O:56])=[O:57])[CH2:53][CH2:54]1)=[O:48])([CH3:45])([CH3:43])[CH3:44]Participants
6
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
Intermediate 1 (Example 2) (0.098 g, 0.286 mmol) was combined with 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (0.060 g, 0.343 mmol) and diluted with DCM (4 mL). This was immediately treated with 4-methyl morpholine (0.063 mL, 0.55 mmol) and allowed to stir at ambient temperature for 1 h. Intermediate 13 (Example 20) (0.130 g, 0.3 mmol) was then added in one portion. Stirring was continued overnight. After 18 h, reaction solvents were removed and resulting crude solids were purified via HPLC to afford the title compound as a white solid (0.056 g, 26%).
Workup
- stirringStirring
- waitwas continued overnight
- waitAfter 18 h
- customreaction solvents
- customwere removed
- customresulting crude solids
- customwere purified via HPLC
Sources & evidence
- ORD record
- ord-831b323d55be4aacb75490498736b872
- Source dataset
- uspto-grants-2011_10
- Patent number
- US08030487B2
Reaction notes
Loading…